Randomized double-blind controlled prospective study on the efficacy of Yizhi Decoction in the treatment of Alzheimer's disease

Wuhan University of Science and Technology0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Residents of the community, those who participate in the community elderly physical examination;
•2. The age is 65-85 years old;
•3. Expected survival period > 1 year;
•4. No tumor, congenital or acquired immunodeficiency disease, congestive heart failure, angina pectoris, myocardial infarction, uncontrolled hypertension or arrhythmia and other serious heart diseases, active hepatitis, liver cirrhosis and other serious liver diseases , Any serious kidney disease such as glomerulonephritis, nephrotic syndrome, uremia, etc., without chronic diarrhea;
•5. Blood routine and electrocardiogram were in the normal range when entering the group, the upper limit of liver and kidney function measurements was <=1.5 times the normal value, blood pressure systolic blood pressure <160mmHg, diastolic blood pressure <100mmHg;
•6. Patients with mild to moderate AD, patients with mild cognitive impairment;
•7. Elderly patients with depression;
•8. Informed consent of patients or their guardians.

•1. Patients with suicidal tendencies, that is, those with a score of >= 2 on the third item of the Hamilton Depression Scale;
•2. Those with a history of drug allergy;
•3. Alcoholism and/or psychoactive substances, drug abusers and dependents (including sleeping pills);
•4. Those who do not use the prescribed medication, cannot judge the efficacy or incomplete data, etc., which affect the judgment of efficacy and safety;
•5. Those who are unable to understand the contents of the scale due to insufficient awareness, language barriers, intelligence and education level (below primary school education);
•6. Visual or hearing impairment prevents the test or assessor.

发起方

Wuhan University of Science and Technology